Effect of Cu(II) Complexation on the Anticancer Activity of Zidovudine in the NCI-60 Human Tumor Cell Line Screen
Zidovudine (AZT, azidothymidine) was originally synthesized as a potential anticancer agent. Originally synthesized in 1964 by Jerome Horwitz at the Michigan Cancer Foundation during efforts to develop antitumor nucleoside analogues, AZT demonstrated insufficient anticancer activity in early evaluations and was not pursued further at that time. Despite its clinical success as an antiviral agent, AZT has continued to attract interest in its anticancer properties, including inhibition of telomerase activity, induction of DNA damage, modulation of cell-cycle progression, and disruption of survival signaling pathways. In the present study, AZT (NSC D-858683) and a Cu(II)-AZT complex (NSC D-858684) were evaluated by the National Cancer Institute Developmental Therapeutics Program using the NCI-60 human tumor cell line panel at a single concentration of 10 μM. AZT exhibited modest antiproliferative activity, producing a mean growth percentage of 98.27% and demonstrating its greatest activity against leukemia and myeloma cell lines. The CuAZT complex produced a similar mean growth percentage (96.05%) but substantially altered tumor selectivity, increasing the response range from 80.22 to 190.27 percentage units. The most notable finding was the emergence of enhanced melanoma activity. CuAZT produced net cell death in MDA-MB-435 melanoma cells (-61.63% growth) and reduced average melanoma growth from approximately 98.9% to 69.4%. These findings suggest that Cu(II) coordination modifies the biological response profile of AZT primarily through changes in tumor selectivity rather than through a substantial increase in overall potency. The distinctive activity profile of CuAZT supports future mechanistic studies and dose-response evaluation. Because Zidovudine (AZT) is still studied and utilized for specific retrovirus-linked cancers, although it is not a general-use chemotherapy drug for common solid tumors, using the 60 cell line panel provides insight to its efficacy against multiple types of cancer. In addition, our use of Cu(II) to improve the efficacy Taxol, raised the question if Cu(II) could do the same for AZT.
Authors
- Thomas J. Manning (ORCID: https://orcid.org/0000-0002-0862-1739)
- Mitchel M Purvis
Publication Details
- Journal
- ChemRxiv
- Published
- 2026-11-19
- DOI
- https://doi.org/10.26434/chemrxiv.15012482/v1
- Primary Topic
- Metal complexes synthesis and properties
- Type
- preprint